Anixa Biosciences’ (ANIX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a report issued on Wednesday,Benzinga reports. They currently have a $10.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

Anixa Biosciences Price Performance

Shares of NASDAQ ANIX opened at $2.97 on Wednesday. The firm’s 50 day simple moving average is $2.77 and its 200-day simple moving average is $3.04. Anixa Biosciences has a 12 month low of $2.07 and a 12 month high of $5.00. The stock has a market capitalization of $95.63 million, a price-to-earnings ratio of -7.62 and a beta of 0.90.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02. Analysts anticipate that Anixa Biosciences will post -0.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The stock was purchased at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the transaction, the director now owns 922,334 shares of the company’s stock, valued at $2,370,398.38. This trade represents a 1.10 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Amit Kumar acquired 43,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was purchased at an average price of $2.23 per share, for a total transaction of $95,890.00. Following the acquisition, the chief executive officer now directly owns 559,925 shares in the company, valued at $1,248,632.75. This represents a 8.32 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 68,289 shares of company stock valued at $157,101. 22.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Anixa Biosciences

A number of hedge funds have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in Anixa Biosciences during the third quarter worth about $34,000. Westside Investment Management Inc. boosted its holdings in shares of Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after purchasing an additional 21,100 shares during the last quarter. Tyler Stone Wealth Management grew its position in shares of Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after purchasing an additional 21,008 shares in the last quarter. Finally, International Assets Investment Management LLC increased its holdings in shares of Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after purchasing an additional 23,800 shares during the last quarter. 29.13% of the stock is currently owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.